Key result
Dapagliflozin reduces CV mortality or HF hospitalization in symptomatic heart failure.
Why the study?
Heart failure causes rising global morbidity and mortality, and a scarcity of research on dapagliflozin prompted an evaluation of whether dapagliflozin 10 mg/day reduces cardiovascular mortality or HF hospitalization in patients with or without type 2 diabetes.
Does dapagliflozin 10 mg/day reduce the risk of cardiovascular mortality or hospitalization for HF in people with or without type 2 diabetes who have or are at risk for atherosclerotic alterations and symptomatic heart failure?
Does dapagliflozin 10 mg/day reduce the risk of cardiovascular mortality or hospitalization for HF in people with or without type 2 diabetes who have or are at risk for atherosclerotic alterations and symptomatic heart failure?
This review highlights dapagliflozin 10 mg/day as an effective and well-tolerated treatment for symptomatic heart failure, reducing cardiovascular mortality and HF hospitalizations regardless of diabetes status.
May support dapagliflozin in symptomatic HF regardless of diabetes; leaves open confirmation by prospective randomized trials.
Heart failure is a prominent clinical condition and a top concern as a widespread health issue. The incidence of heart failure is rising alarmingly on a global scale. Heart failure significantly strains the whole healthcare system financially, degrading the patient's quality of life and increasing the risk of morbidity and mortality. Heart failure treatment has changed over time with ongoing research and the development of new medications and equipment. Recently, the FDA and European Union (EU) approved the drug dapagliflozin, which is an inhibitor of sodium-glucose cotransporter 2 (SGLT-2i), for treating people with cardiovascular conditions and symptomatic heart failure (HF). In this review article, we will find out whether Dapagliflozin, when given at a dose of 10 mg/day in people with type 2 diabetes and in those without type 2 diabetes who have or are at risk for atherosclerotic alterations, can considerably lower the risk of cardiovascular mortality or hospitalization for HF. In the presence of concomitant HF therapies, dapagliflozin's benefits remained. Dapagliflozin's overall safety profile was comparable to its safety profile for other applications. It was often well tolerated in patients in a study group. In this review article, dapagliflozin is found to be the well-tolerated and effective novel treatment of choice for symptomatic HF. Because of the scarcity of research on dapagliflozin, it was necessary to provide data to help reduce the mortality of patients while providing further guidance on the clinical medication of dapagliflozin.
No takes yet. Share an insight, caveat, or question.
Palandurkar et al. (2022) conducted a review in Symptomatic heart failure. Dapagliflozin was evaluated on Cardiovascular mortality or hospitalization for HF. Dapagliflozin at 10 mg/day is a well-tolerated and effective novel treatment for symptomatic heart failure, reducing the risk of cardiovascular mortality or hospitalization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: